Viewpoint published in JAMA Internal Medicine assesses the current format of pharmacy leaflets and offers suggestions for improvements to make benefit and risk information more accessible to patients and caregivers.

Special event recognizes students Maya Hanna, Patience Moyo, Priyanka Gaitonde, and Joseph Vandigo for their superior academic performance.

First-of-its-kind event brings alumni from the PhD in Pharmaceutical Sciences (PSC) program together to reconnect with the School and discuss career experiences with current graduate students.

New grants and contracts from a multitude of non-profit and government organizations, as well as the private sector, help the School of Pharmacy achieve the highest funding increase among all professional and graduate schools at the University of Maryland, Baltimore.

Leading health solutions company will support genotyping services for students in the School’s advanced pharmacogenomics course.

Week-long workshop featured presentations, panel discussions, and other activities designed to broaden participants’ knowledge of comparative effectiveness research and patient-centered outcomes research.

More than 500 researchers from academia, government, and industry gather to gain perspective on biomarker development and the application of biomarkers in preclinical and clinical research.

Collaborative study helps validate effectiveness of FDA’s bioequivalence standard, showing no significant differences between major brand name and generic medication used to treat patients with epilepsy.

Graduate program co-founder Dr. Frank Palumbo assumes leadership of program, allowing previous director, Dr. Ebere Onukwugha, to focus on her work as executive director of the department’s Pharmaceutical Research Computing center.

Testimony examined the impact of FDA-supported research in generic drugs and advocated for continued funding through renewal of the Generic Drug User Fee Amendments of 2012 (GDUFA).